Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges

  title={Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges},
  author={Celina Dubin and Ester Del Duca and Emma Guttman‐Yassky},
  journal={Therapeutics and Clinical Risk Management},
  pages={1319 - 1332}
Abstract Chronic hand eczema (CHE) is a common and burdensome inflammatory skin condition seen in up to 10% of the population, more often in high-risk occupational workers. Topical therapeutics comprise the standard of care, but up to 65% of cases do not resolve after treatment, and moderate-to-severe cases are often resistant to topical therapeutics and require systemic options instead. To date, there are no systemic therapeutics approved to treat CHE in the United States, but several drugs… 
Alitretinoin for the treatment of severe chronic eczema of the hands
Alitretinoin can be considered as a valid therapeutic option for the treatment of CHE in patients not responding to ordinary treatments, and acts effectively on both objective and subjective clinical signs, resulting in a significant improvement in QoL of patients.
Steroid-refractory hand eczema: treatment experience
The use of this multicomponent drug in monotherapy for hand eczema is effective, leads to clinical remission and restoration of the quality of life of patients and is not accompanied by side effects and complications.
Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis
Although topical JAK inhibitors have promising efficacy and safety profiles, poor medication adherence common to topical treatments may limit their utility in a clinical setting.
Baricitinib treatment of severe chronic hand eczema: Two case reports
A phase II clinical trial using Camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma and safety, activity, and biomarkers of SHR1210, an anti-PD-1 antibody, for patients with advanced esphageal carcinoma are presented.
Occupational Dermatitis Treated with Alitretinoin
A hairdresser who presented with occupational allergic contact dermatitis and was treated with alitretinoin is described, which allows us to tackle the physical, psychosocial and cost-related burdens that this disorder brings.
The JAK/STAT signaling pathway: from bench to clinic
In this review, the current knowledge about the composition, activation, and regulation of the JAK/STAT pathway is discussed and the role of this signaling pathway and its inhibitors in various diseases is highlighted.


Alitretinoin: A Review in Severe Chronic Hand Eczema
Oral alitretinoin is a useful treatment option for patients with severe chronic hand eczema unresponsive to potent topical corticosteroids, and data obtained in real-world studies were consistent with those observed in clinical trials.
Management of chronic hand and foot eczema. An Australia/New Zealand Clinical narrative
Management of chronic hand/foot eczemas extends beyond mere pharmacological or physical treatment, and requires an encompassing approach including removal or avoidance of causative factors, behavioural changes and social support.
Management of chronic hand eczema
It is concluded that despite the abundance of topical and systemic treatment options, disease management in patients with severe chronic HE is frequently inadequate and there is a strong need for RCTs of existing and new treatment options based on clearly diagnosed subtypes of HE and its severity.
Alitretinoin for the treatment of chronic hand eczema: clinical rationale
This review summarizes the advances on oral alitretinoin for the treatment of severe CHE, with emphasis on its particular benefit for hyperkeratotic hand eczema, and discusses pharmacodynamics and pharmacokinetics, clinical trials and knowledge gaps.
Current and emerging therapies for hand eczema
Several agents that target IL‐4 and IL‐13 signaling, keratinocyte proliferation, inflammatory cytokine production, bacterial protein synthesis, and inflammatory mediator proliferation are shown to be involved in the pathogenesis of CHE.
Consensus statement on the management of chronic hand eczema
The epidemiology and pathogenesis of hand eczema, its diagnosis and its effect on patients’ quality of life are described, and recommendations for management are summarized in a treatment algorithm.
Topical agents for the treatment of atopic dermatitis
A comprehensive overview of new and upcoming topical therapies currently in development and undergoing clinical trials, as well as their safety and efficacy profiles, are provided, and current topicals used in the management of AD are discussed.
Management of Chronic Hand Eczema.
Alitretinoin as a potential advance in the management of severe chronic hand eczema.
Oral alitretinoin at a dose of 10 or 30 mg once daily is an effective and safe treatment for severe chronic hand eczema refractory to topical corticosteroids and a patient global assessment of “clear” or “almost clear” at the end of therapy is found.
Efficacy and safety of low dose Methotrexate in the treatment of chronic hand eczema
Low dose oral Methotrexate ( 0.1 mg/kg body weight once weekly) is effective and safe but not a better option than topical clobetasol propionate (0.05%) in chronic hand eczema.